{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:24Z","timestamp":1790812704661,"version":"4.1.0"},"reference-count":282,"publisher":"Centers for Disease Control MMWR Office","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr7401a1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:12:53Z","timestamp":1746537173000},"page":"1-56","source":"Crossref","is-referenced-by-count":32,"title":["Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV \u2014 CDC Recommendations, United States, 2025"],"prefix":"10.15585","volume":"74","author":[{"given":"Mary R.","family":"Tanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema G.","family":"Dumitru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Lale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy K.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetam","family":"Cholli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena P.","family":"Kourtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R136","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10865-018-9922-y","article-title":"Experiences of stigma and health care engagement among Black MSM newly diagnosed with HIV\/STI.","volume":"41","author":"Eaton","year":"2018","journal-title":"J Behav Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R137","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s10461-018-2375-z","article-title":"\u201cA gay man and a doctor are just like, a recipe for destruction\u201d: how racism and homonegativity in healthcare settings influence PrEP uptake among young Black MSM.","volume":"23","author":"Quinn","year":"2019","journal-title":"AIDS Behav"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R138","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings.","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R139","doi-asserted-by":"publisher","first-page":"e0224335","DOI":"10.1371\/journal.pone.0224335","article-title":"\u201cYou\u2019re kind of at war with yourself as a nurse\u201d: perspectives of inpatient nurses on treating people who present with a comorbid opioid use disorder.","volume":"14","author":"Horner","year":"2019","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R140","doi-asserted-by":"publisher","first-page":"CD003255","DOI":"10.1002\/14651858.CD003255","article-title":"Condom effectiveness in reducing heterosexual HIV transmission.","volume":"2002","author":"Weller","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R141","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/QAI.0000000000000461","article-title":"Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States.","volume":"68","author":"Smith","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R142","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/QAD.0000000000001832","article-title":"Per-partner condom effectiveness against HIV for men who have sex with men.","volume":"32","author":"Johnson","year":"2018","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R143","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R144","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R145","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R146","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R147","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/stacks.cdc.gov\/view\/cdc\/20711"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R148","unstructured":"Dasgupta S, Tie Y, Beer L,  Behavioral and clinical characteristics of persons with diagnosed HIV infection\u2014Medical Monitoring Project, United States, 2020 cycle (June 2020\u2013May 2021). Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/110355"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R149","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R150","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R151","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission.","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R152","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/QAI.0000000000002912","article-title":"Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure.","volume":"90","author":"Mayer","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R153","unstructured":"New York State Department of Health AIDS Institute. Clinical Guidelines Program: PEP and PREP\u2014PEP to prevent HIV infection; 2024. Albany, NY: New York State Department of Health. https:\/\/www.hivguidelines.org\/guideline\/hiv-pep\/?mycollection\u00a0=\u00a0pep-prep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R154","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/OLQ.0b013e3181812d15","article-title":"The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis.","volume":"35","author":"Johnson","year":"2008","journal-title":"Sex Transm Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R155","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1600-0897.2010.00942.x","article-title":"Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition.","volume":"65","author":"Mayer","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R156","unstructured":"CDC. Sexually transmitted infections treatment guidelines, 2021. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/default.htm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R157","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: a systematic review.","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R158","unstructured":"CDC. How HIV spreads. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/www.cdc.gov\/hiv\/causes\/?CDC_AAref_Val#cdc_causes_risk-risk-factors"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R159","first-page":"61","article-title":"The management of needlestick injuries.","volume":"110","author":"Himmelreich","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R160","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/1570162X18666200804151118","article-title":"Clinical outcomes of post-exposure prophylaxis following occupational exposure to human immunodeficiency virus at dental departments of Hiroshima University Hospital.","volume":"18","author":"Shintani","year":"2020","journal-title":"Curr HIV Res"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R161","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/QAD.0000000000001039","article-title":"HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks.","volume":"30","author":"Des Jarlais","year":"2016","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R162","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1097\/QAI.0000000000002062","article-title":"Sharing of injection drug preparation equipment is associated with HIV infection: a cross-sectional study.","volume":"81","author":"Ball","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R163","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(96)90838-7","article-title":"Transmission of HIV-1 by human bite.","volume":"347","author":"Vidmar","year":"1996","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R164","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-6405-8-16","article-title":"Possible transmission of HIV infection due to human bite.","volume":"8","author":"Deshpande","year":"2011","journal-title":"AIDS Res Ther"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R165","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/088922204323048087","article-title":"HIV type 1 transmission by human bite.","volume":"20","author":"Andreo","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R166","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/hiv.12625","article-title":"A systematic review of risk of HIV transmission through biting or spitting: implications for policy.","volume":"19","author":"Cresswell","year":"2018","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R167","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1017\/ice.2020.82","article-title":"Transmission of human immunodeficiency virus (HIV) to a family caregiver through a conjunctival blood splash.","volume":"41","author":"Lang","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R168","first-page":"1245","article-title":"Notes from the field: occupationally acquired HIV infection among health care workers\u2014United States, 1985\u20132013.","volume":"63","author":"Joyce","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R169","doi-asserted-by":"crossref","unstructured":"Kuhar DT, Henderson DK, Struble KA,  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. https:\/\/stacks.cdc.gov\/view\/cdc\/20711","DOI":"10.1086\/672271"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R170","first-page":"1374","article-title":"When is postexposure prophylaxis recommended for needlestick?","volume":"83","author":"Matin","year":"2011","journal-title":"Am Fam Physician"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R171","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.1986.03370140085029","article-title":"Stability and inactivation of HTLV-III\/LAV under clinical and laboratory environments.","volume":"255","author":"Resnick","year":"1986","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R172","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00006454-199807000-00018","article-title":"Detection of infectious human immunodeficiency type 1 virus in discarded syringes of intravenous drug users.","volume":"17","author":"Zamora","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R173","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1086\/497268","article-title":"Seroconversion following nonoccupational postexposure prophylaxis against HIV.","volume":"41","author":"Roland","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R174","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/ciz577","article-title":"Elvitegravir\u2013cobicistat\u2013emtricitabine\u2013tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis.","volume":"70","author":"Gantner","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R175","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0956462417743158","article-title":"Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.","volume":"29","author":"Beymer","year":"2018","journal-title":"Int J STD AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R176","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/jac\/dkw049","article-title":"A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.","volume":"71","author":"Leal","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R177","doi-asserted-by":"publisher","first-page":"e27563","DOI":"10.1097\/MD.0000000000027563","article-title":"Implementation of HIV non-occupational post-exposure prophylaxis for men who have sex with men in 2 cities of Southwestern China.","volume":"100","author":"Wu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R178","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1093\/jac\/dkx246","article-title":"Tenofovir disoproxil fumarate\/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.","volume":"72","author":"Inciarte","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R179","doi-asserted-by":"publisher","first-page":"e0142534","DOI":"10.1371\/journal.pone.0142534","article-title":"Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort.","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R180","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1093\/cid\/civ092","article-title":"Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.","volume":"60","author":"Ford","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R181","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jinf.2017.10.008","article-title":"Adherence to HIV post-exposure prophylaxis: a multivariate regression analysis of a 5 years prospective cohort.","volume":"76","author":"Malinverni","year":"2018","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R182","first-page":"23","article-title":"Acute HIV infection after initiation of post-exposure prophylaxis following sexual exposure: reasons, challenges and suggested management.","volume":"16","author":"Haidari","year":"2015","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R183","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/QAI.0000000000002912","article-title":"Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure.","volume":"90","author":"Mayer","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R184","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1097\/CM9.0000000000002494","article-title":"An open-label evaluation of safety and tolerability of coformulated bictegravir\/emtricitabine\/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1.","volume":"135","author":"Liu","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R185","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/hiv.12880","article-title":"Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.","volume":"21","author":"Gantner","year":"2020","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R186","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/QAD.0000000000001447","article-title":"Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.","volume":"31","author":"McAllister","year":"2017","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R187","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","article-title":"Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China.","volume":"10","author":"Nie","year":"2021","journal-title":"Infect Dis Ther"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R188","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QAI.0000000000001440","article-title":"Optimal HIV postexposure prophylaxis regimen completion with single tablet daily elvitegravir\/cobicistat\/tenofovir disoproxil fumarate\/emtricitabine compared with more frequent dosing regimens.","volume":"75","author":"Mayer","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R189","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12879-016-2056-3","article-title":"Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.","volume":"16","author":"Valin","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R190","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/sextrans-2020-054714","article-title":"Single-tablet regimen of emtricitabine\/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.","volume":"97","author":"Malinverni","year":"2021","journal-title":"Sex Transm Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R191","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/QAI.0b013e31824a03b8","article-title":"Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.","volume":"59","author":"Mayer","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R192","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.ajem.2017.05.054","article-title":"Two, three, and four-drug regimens for HIV post-exposure prophylaxis in a North American sexual assault victim population.","volume":"35","author":"Kumar","year":"2017","journal-title":"Am J Emerg Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R193","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/hiv.12797","article-title":"Post-exposure prophylaxis for HIV infection in sexual assault victims.","volume":"21","author":"Inciarte","year":"2020","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R194","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/sextrans-2015-052262","article-title":"Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug-drug interactions (DDIs) with improved adherence and tolerability.","volume":"92","author":"Mulka","year":"2016","journal-title":"Sex Transm Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R195","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/hiv.12938","article-title":"Once-daily raltegravir with tenofovir disoproxil\/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.","volume":"22","author":"Quah","year":"2021","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R196","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s12024-018-9985-7","article-title":"The use of HIV post-exposure prophylaxis in forensic medicine following incidents of sexual violence in Hamburg, Germany: a retrospective study.","volume":"14","author":"Ebert","year":"2018","journal-title":"Forensic Sci Med Pathol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R197","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1097\/QAI.0000000000000680","article-title":"Changes to initial postexposure prophylaxis regimens between the emergency department and clinic.","volume":"69","author":"Bogoch","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R198","doi-asserted-by":"publisher","first-page":"e13777","DOI":"10.7759\/cureus.13777","article-title":"HIV post exposure prophylaxis and risk of relapse in adolescent with bipolar illness and psychopharmacologic challenges.","volume":"13","author":"Gupta","year":"2021","journal-title":"Cureus"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R199","unstructured":"Nolan A, Yarosh D, Shaikh S. Mitigating risk: post-exposure prophylaxis in liver transplant recipients from donors with potential infectious exposure [Poster]. 2018 American Transplant Congress; June 2\u20136, 2018, Seattle, WA."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R200","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/hiv.12363","article-title":"PEPDar: a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.","volume":"17","author":"F\u00e4tkenheuer","year":"2016","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R201","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3389\/fgene.2020.00497","article-title":"Mitochondrial toxicogenomics for antiretroviral management: HIV post-exposure prophylaxis in uninfected patients.","volume":"11","author":"Ba\u00f1\u00f3","year":"2020","journal-title":"Front Genet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R202","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1071\/SH16132","article-title":"Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system.","volume":"14","author":"Pierce","year":"2017","journal-title":"Sex Health"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R203","first-page":"64","article-title":"CSHP Professional Practice Conference 2011: poster abstracts\/conf\u00e9rence sur la pratique professionnelle 2011 de la SCHP: r\u00e9sum\u00e9s des affiches.","volume":"64","year":"2011","journal-title":"Can J Hosp Pharm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R204","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/23744235.2015.1103896","article-title":"The Danish PEP Registry: experience with the use of post-exposure prophylaxis following blood exposure to HIV from 1999\u20132012.","volume":"48","author":"Lunding","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R205","first-page":"84","article-title":"Tolerability of darunavir\/ritonavir, tenofovir\/emtricitabine for human immunodeficiency virus postexposure prophylaxis.","volume":"68","author":"Hutton","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R206","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10461-016-1536-1","article-title":"Anti-retroviral therapy based HIV prevention among a sample of men who have sex with men in Cape Town, South Africa: use of post-exposure prophylaxis and knowledge on pre-exposure prophylaxis.","volume":"20","author":"Hugo","year":"2016","journal-title":"AIDS Behav"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R207","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/QAD.0000000000000563","article-title":"Acute interstitial nephritis caused by lopinavir\/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis.","volume":"29","author":"Chughlay","year":"2015","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R208","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12889-015-1928-6","article-title":"Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.","volume":"15","author":"Tetteh","year":"2015","journal-title":"BMC Public Health"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R209","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdmv.2020.12.002","article-title":"Ergotism with acute limb ischemia, provoked by HIV protease inhibitors interaction with ergotamine, rescued by multisite transluminal balloon angioplasty.","volume":"46","author":"Mohamedi","year":"2021","journal-title":"J Med Vasc"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R210","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5114\/aoms.2016.59701","article-title":"Suspected unexpected and other adverse reactions to antiretroviral drugs used as post-exposure prophylaxis of HIV infection\u2014five-year experience from clinical practice.","volume":"14","author":"Kowalska","year":"2018","journal-title":"Arch Med Sci"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R211","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/QAD.0000000000001054","article-title":"Tenofovir disoproxil fumarate-induced Fanconi\u2019s syndrome during HIV postexposure prophylaxis.","volume":"30","author":"Penot","year":"2016","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R212","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.amjmed.2014.10.060","article-title":"Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.","volume":"128","author":"Alves","year":"2015","journal-title":"Am J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R213","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jac\/dky547","article-title":"Tenofovir DF\/emtricitabine\/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.","volume":"74","author":"Chauveau","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R214","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/cid\/civ511","article-title":"Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men.","volume":"61","author":"Foster","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R215","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhin.2015.12.015","article-title":"Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis.","volume":"92","author":"Wiboonchutikul","year":"2016","journal-title":"J Hosp Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R216","doi-asserted-by":"publisher","first-page":"176","DOI":"10.11910\/2227-6394.2018.06.04.04","article-title":"Epidemiological and clinical information of people at risk for HIV referred to the voluntary counseling and testing center, Tehran, Iran, 2013\u20132014.","volume":"6","author":"Rasoolinejad","year":"2018","journal-title":"J Int Translational Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R217","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1093\/ofid\/ofw172.374","article-title":"Tolerability of tenofovir-lamivudine-rilpivirine as the human immunodeficiency virus (HIV) occupational post-exposure prophylaxis for HIV infection [Abstract].","volume":"3","author":"Chavapong","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R218","first-page":"257","article-title":"Tolerability and treatment completion of tenofovir alafenamide\/emtricitabine\/rilpivirine (TAF\/FTC\/RPV) as HIV postexposure prophylaxis.","volume":"20","author":"Chauveau","year":"2019","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R219","unstructured":"US Department of Health Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: US Department of Health and Human Services; 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R220","unstructured":"Mikati T, Crawley A, Daskalakis D. Are routine renal and liver labs testing among PEP patients on TDF\/FTC\/DTV necessary?[Abstract 983]. Conference on Retroviruses and Opportunistic Infections, Seattle, WA: March 4\u20137, 2019."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R221","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R222","doi-asserted-by":"publisher","first-page":"A219","DOI":"10.1136\/ejhpharm-2019-eahpconf.471","article-title":"5PSQ-038 Safety and effectiveness of HIV post-exposure prophylaxis.","volume":"26","author":"Fernandes","year":"2019","journal-title":"Euro J Hosp Pharm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R223","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0956462413481528","article-title":"Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome\u2014implications for clinical practice and patient safety.","volume":"24","author":"Perry","year":"2013","journal-title":"Int J STD AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R224","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/QAI.0b013e3182832578","article-title":"Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults.","volume":"62","author":"Lee","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R225","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cix096","article-title":"Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir.","volume":"64","author":"Thomas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R226","first-page":"46","article-title":"Case study: a 13 year old boy\u2019s post exposure prophylaxis was stopped prematurely due to raltegravir induced thrombocytopenia.","volume":"31","author":"Stockwell","year":"2020","journal-title":"Int J STD AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R227","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R228","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R229","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.","volume":"3","author":"Squires","year":"2016","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R230","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R231","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R232","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R233","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R234","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir.","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R235","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/AAC.06170-11","article-title":"Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.","volume":"56","author":"Garrido","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R236","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/cid\/ciy228","article-title":"Emergence of integrase resistance mutations during initial therapy containing dolutegravir.","volume":"67","author":"Fulcher","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R237","doi-asserted-by":"publisher","first-page":"ofy332","DOI":"10.1093\/ofid\/ofy332","article-title":"Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible.","volume":"6","author":"Pena","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R238","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1056\/NEJMc1806554","article-title":"Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R.","volume":"381","author":"L\u00fcbke","year":"2019","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R239","doi-asserted-by":"publisher","first-page":"104717","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.","volume":"179","author":"Lozano","year":"2020","journal-title":"Antiviral Res"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R240","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R241","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials.","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R242","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R243","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R244","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7326\/0003-4819-127-10-199711150-00017","article-title":"New-onset diabetes mellitus associated with use of protease inhibitor.","volume":"127","author":"Eastone","year":"1997","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R245","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jinf.2010.06.002","article-title":"The HIV-1\/HAART associated metabolic syndrome\u2014novel adipokines, molecular associations and therapeutic implications.","volume":"61","author":"Tsiodras","year":"2010","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R246","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/QAD.0b013e328341dcc0","article-title":"Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.","volume":"25","author":"Soliman","year":"2011","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R247","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-127-10-199711150-00016","article-title":"Severe diabetes associated with protease inhibitor therapy.","volume":"127","author":"Visnegarwala","year":"1997","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R248","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4212\/cjhp.v68i1.1428","article-title":"CSHP Professional Practice Conference 2015: poster abstracts\/conf\u00e9rence sur la pratique professionnelle 2015 de la SCPH: r\u00e9sum\u00e9s des affiches.","volume":"68","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R249","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/QAD.0b013e32813aee35","article-title":"Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration\u2019s Adverse Event Reporting System.","volume":"21","author":"Chan-Tack","year":"2007","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R250","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1097\/QAD.0b013e32834a1cd6","article-title":"Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.","volume":"25","author":"Rockwood","year":"2011","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R251","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/cid\/cis621","article-title":"High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.","volume":"55","author":"Hamada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R252","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R253","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/cid\/cis620","article-title":"Complicated atazanavir-associated cholelithiasis: a report of 14 cases.","volume":"55","author":"Rakotondravelo","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R254","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R255","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","article-title":"Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.","volume":"27","author":"Monforte","year":"2013","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R256","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R257","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.","volume":"170","author":"Lang","year":"2010","journal-title":"Arch Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R258","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1086\/652149","article-title":"Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.","volume":"50","author":"Evans-Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R259","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/QAD.0b013e328335cd8a","article-title":"Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial.","volume":"24","author":"Gardner","year":"2010","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R260","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial.","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R261","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00365548.2013.773067","article-title":"Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.","volume":"45","author":"Leutscher","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R262","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R263","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jce.13032","article-title":"Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers.","volume":"27","author":"Abdelhady","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R264","doi-asserted-by":"publisher","first-page":"1270716","DOI":"10.1155\/2018\/1270716","article-title":"Acute liver failure among patients on efavirenz-based antiretroviral therapy.","volume":"2018","author":"Segamwenge","year":"2018","journal-title":"Case Reports Hepatol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R265","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.","volume":"15","author":"Carey","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R266","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial.","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R267","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R268","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R269","doi-asserted-by":"publisher","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.","volume":"276","author":"Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R270","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R271","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R272","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R273","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R274","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J Virus Erad"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R275","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides.","volume":"9","author":"Mallon","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R276","doi-asserted-by":"publisher","first-page":"e79981","DOI":"10.1371\/journal.pone.0079981","article-title":"Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.","volume":"8","author":"Ford","year":"2013","journal-title":"PLoS One"},{"issue":"236","key":"key-10.15585\/mmwr.rr7401a1-202505201510-R277","first-page":"1","article-title":"Lamivudine (3TC) approved for combination use with AZT.","author":"James","year":"1995","journal-title":"AIDS Treat News"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R278","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/QAI.0000000000000403","article-title":"Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.","volume":"68","author":"Jain","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R279","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","author":"Strategies for Management of Anti-Retroviral Therapy\/INSIGHT Study Group; DAD Study Group","year":"2008","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R280","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QAI.0000000000000881","article-title":"Use of abacavir and risk of cardiovascular disease among HIV-infected individuals.","volume":"71","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R281","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/clpt.2008.168","article-title":"Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.","volume":"85","author":"Mathias","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R282","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QAI.0b013e3182645648","article-title":"Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.","volume":"61","author":"German","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R1","unstructured":"CDC. HIV surveillance report: diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/156509"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R2","doi-asserted-by":"crossref","unstructured":"Kuhar DT, Henderson DK, Struble KA,  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. https:\/\/stacks.cdc.gov\/view\/cdc\/20711","DOI":"10.1086\/672271"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R3","unstructured":"Dominguez KL, Smith DK, Thomas V,  Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV\u2014United States, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https:\/\/stacks.cdc.gov\/view\/cdc\/38856"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R4","unstructured":"CDC. Sexually transmitted infections treatment guidelines, 2021. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/default.htm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R5","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R6","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. Washington, DC: US Department of Health and Human Services; 2023. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/perinatal-hiv\/guidelines-perinatal.pdf"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R8","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3018(23)00238-2","article-title":"Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.","volume":"10","author":"Mayer","year":"2023","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R9","unstructured":"Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation; 2024. https:\/\/www.covidence.org\/"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R10","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.svwngs6pm0f2"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/bmjebm-2022-111962","article-title":"Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance.","volume":"28","author":"Dewidar","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R12","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142017 update. A clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2018:1\u201377. https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R13","unstructured":"Wells GA, Shea B, O\u2019Connell D,  The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario: Ottawa Hospital Research Institute; 2014. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R14","unstructured":"US Preventive Services Task Force. Procedure manual section 7. Formulation of task force recommendations. Rockville, MD: US Preventive Services Task Force; 2017. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual\/procedure-manual-section-7-formulation-task-force-recommendations"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R15","unstructured":"Office of Management and Budget. Final information quality bulletin for peer review. Washington, DC: Office of Management and Budget; 2005. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2005-01-14\/pdf\/05-769.pdf"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.15585\/mmwr.mm6547e1","article-title":"Vital Signs: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs - United States.","volume":"65","author":"Wejnert","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R17","unstructured":"New York State Department of Health AIDS Institute. Clinical Guidelines Program: PEP to prevent HIV infection. Albany, NY: New York State Department of Health; 2024. https:\/\/www.hivguidelines.org\/guideline\/hiv-pep\/?mycollection=pep-prep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: a systematic review.","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00000433-199909000-00003","article-title":"Human bites and the risk of human immunodeficiency virus transmission.","volume":"20","author":"Pretty","year":"1999","journal-title":"Am J Forensic Med Pathol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/QAI.0000000000002912","article-title":"Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure.","volume":"90","author":"Mayer","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R21","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.","volume":"29","author":"Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R23","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/cid\/ciad021","article-title":"Updating the adherence\u2013response for oral emtricitabine\/tenofovir disoproxil fumarate for human immunodeficiency virus pre-exposure prophylaxis among cisgender women.","volume":"76","author":"Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine.","volume":"214","author":"Cottrell","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R25","doi-asserted-by":"publisher","first-page":"ofx061","DOI":"10.1093\/ofid\/ofx061","article-title":"Differentiating nonoccupational postexposure prophylaxis seroconverters and non-seroconverters in a community-based clinic in Los Angeles, California.","volume":"4","author":"Beymer","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R26","doi-asserted-by":"publisher","first-page":"9771","DOI":"10.1128\/JVI.74.20.9771-9775.2000","article-title":"Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).","volume":"74","author":"Otten","year":"2000","journal-title":"J Virol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R27","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1038\/s41467-018-07881-9","article-title":"Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.","volume":"9","author":"Whitney","year":"2018","journal-title":"Nat Commun"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R28","unstructured":"CDC. Clinical testing guidance for HIV. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/hivnexus\/hcp\/diagnosis-testing\/index.html"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R29","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1128\/JVI.72.5.4265-4273.1998","article-title":"Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.","volume":"72","author":"Tsai","year":"1998","journal-title":"J Virol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAD.0b013e328321302d","article-title":"Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir.","volume":"23","author":"Bourry","year":"2009","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R31","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1097\/00002030-200008180-00029","article-title":"Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV\/HIV chimera.","volume":"14","author":"Le Grand","year":"2000","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R32","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1093\/cid\/civ069","article-title":"Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies.","volume":"60","author":"Irvine","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1086\/342389","article-title":"Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.","volume":"35","author":"Chaudry","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jac\/dkac419","article-title":"Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.","volume":"78","author":"Haaland","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R35","doi-asserted-by":"publisher","first-page":"112re4","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci Transl Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1086\/344311","article-title":"Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.","volume":"186","author":"Reddy","year":"2002","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/jac\/dkaa476","article-title":"Two-dose emtricitabine\/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.","volume":"76","author":"Bekerman","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R38","doi-asserted-by":"publisher","first-page":"227ra35","DOI":"10.1126\/scitranslmed.3007701","article-title":"Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.","volume":"6","author":"Dobard","year":"2014","journal-title":"Sci Transl Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R39","doi-asserted-by":"publisher","first-page":"104361","DOI":"10.1016\/j.ebiom.2022.104361","article-title":"Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.","volume":"86","author":"Dobard","year":"2022","journal-title":"EBioMedicine"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R40","doi-asserted-by":"publisher","first-page":"102894","DOI":"10.1016\/j.ebiom.2020.102894","article-title":"Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.","volume":"58","author":"Massud","year":"2020","journal-title":"EBioMedicine"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018.","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAD.0000000000002394","article-title":"HIV drug resistance in a cohort of HIV-infected MSM in the United States.","volume":"34","author":"Fogel","year":"2020","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00126334-200404150-00010","article-title":"Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.","volume":"35","author":"Schechter","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R45","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1093\/cid\/civ092","article-title":"Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.","volume":"60","author":"Ford","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R46","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/QAD.0000000000001447","article-title":"Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.","volume":"31","author":"McAllister","year":"2017","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R47","unstructured":"US Department of Health Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: US Department of Health and Human Services; 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R48","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3389\/fgene.2020.00497","article-title":"Mitochondrial toxicogenomics for antiretroviral management: HIV post-exposure prophylaxis in uninfected patients.","volume":"11","author":"Ba\u00f1\u00f3","year":"2020","journal-title":"Front Genet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R50","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/QAD.0b013e32832b43f2","article-title":"Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV\/HBV coinfected individuals.","volume":"23","author":"Matthews","year":"2009","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R51","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/hep.21388","article-title":"Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.","volume":"44","author":"Peters","year":"2006","journal-title":"Hepatology"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R53","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.","volume":"15","author":"Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women.","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R56","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/1359105305051421","article-title":"The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy.","volume":"10","author":"Halkitis","year":"2005","journal-title":"J Health Psychol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R58","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jadohealth.2011.12.013","article-title":"Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV.","volume":"51","author":"Chandwani","year":"2012","journal-title":"J Adolesc Health"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R59","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.amepre.2012.09.047","article-title":"Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies.","volume":"44","author":"Koenig","year":"2013","journal-title":"Am J Prev Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R60","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R61","unstructured":"CDC. Technical update for HIV nucleic acid tests approved for diagnostic purposes. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/129018"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcv.2015.12.011","article-title":"Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM.","volume":"76","author":"Stekler","year":"2016","journal-title":"J Clin Virol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R63","unstructured":"CDC. About HIV. Atlanta, GA: US Department of Health and Human Services, CDC; 2025. https:\/\/www.cdc.gov\/hiv\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/hiv\/basics\/whatishiv.html"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R64","unstructured":"CDC. How HIV spreads. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/hiv\/causes\/index.html"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/QAI.0000000000001374","article-title":"Characterization of HIV Seroconverters in a TDF\/FTC PrEP Study: HPTN 067\/ADAPT.","volume":"75","author":"Sivay","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R66","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1097\/QAD.0000000000001577","article-title":"The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.","volume":"31","author":"Donnell","year":"2017","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R67","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083.","volume":"224","author":"Marzinke","year":"2021","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/ciw666","article-title":"Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure.","volume":"64","author":"Delaney","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0956462414542987","article-title":"Probability of a false-negative HIV antibody test result during the window period: a tool for pre- and post-test counselling.","volume":"26","author":"Taylor","year":"2015","journal-title":"Int J STD AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R70","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/cells10051263","article-title":"Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data.","volume":"10","author":"Otto","year":"2021","journal-title":"Cells"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R71","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R74","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R75","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1097\/CM9.0000000000003147","article-title":"Changes in blood lipid levels and influencing factors among treatment-na\u00efve adult male HIV\/AIDS patients following BIC\/FTC\/TAF vs. 3TC+EFV+TDF.","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R76","unstructured":"CDC. Sexual assault and abuse and STIs\u2014adolescents and adults. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/sexual-assault-adults.htm"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R78","unstructured":"CDC. Interim clinical considerations for use of JYNNEOS vaccine for mpox prevention in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/vaccines\/vaccine-considerations.html#print"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R79","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"DoxyPEP Study Team. Postexposure doxycycline to prevent bacterial sexually transmitted infections.","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","article-title":"CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.","volume":"73","author":"Bachmann","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R81","unstructured":"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Alexandria, VA: American Association for the Study of Liver Diseases and Arlington, VA: Infectious Diseases Society of America; 2023. https:\/\/www.hcvguidelines.org\/"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R82","unstructured":"Food and Drug Administration. Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/164829\/download"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R85","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","article-title":"No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting.","volume":"61","author":"Volk","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R86","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/cid\/cix593","article-title":"Redefining human immunodeficiency virus (HIV) preexposure prophylaxis failures.","volume":"65","author":"Marcus","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5114\/hivar.2017.65199","article-title":"When effective post-exposure prophylaxis of HIV infection fails\u2013data from clinical practice.","volume":"16","author":"Kowalska","year":"2017","journal-title":"HIV AIDS Rev"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R88","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41467-021-21485-w","article-title":"Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis.","volume":"12","author":"Hovaguimian","year":"2021","journal-title":"Nat Commun"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R89","doi-asserted-by":"publisher","first-page":"e0142534","DOI":"10.1371\/journal.pone.0142534","article-title":"Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort.","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R90","unstructured":"CDC. Issue brief: status neutral HIV care and service delivery. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/129024"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R91","unstructured":"Center for Substance Abuse Treatment (US). Trauma-informed care: a sociocultural perspective [Chapter 1]. In: Trauma-informed care in behavioral health services, treatment improvement protocol (TIP) series, no. 57. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK207195\/"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R92","unstructured":"National Alliance of State & Territorial AIDS Directors. Trauma-informed approaches toolkit: addressing trauma and supporting healing within the HIV care delivery system. Washington, DC: National Alliance of State & Territorial AIDS Directors; 2022. https:\/\/targethiv.org\/sites\/default\/files\/media\/documents\/2023-01\/Trauma-Informed-Approaches-Toolkit-2022_NASTAD.pdf"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R93","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1097\/AOG.0000000000003178","article-title":"ACOG Committee opinion no. 777: sexual assault.","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R94","unstructured":"National Institute of Mental Health. Ask suicide-screening questions (ASQ) toolkit. Bethesda, MD: National Institute of Mental Health. https:\/\/www.nimh.nih.gov\/research\/research-conducted-at-nimh\/asq-toolkit-materials"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R95","unstructured":"Substance Abuse and Mental Health Services Administration. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2024. https:\/\/www.samhsa.gov\/substance-use\/treatment\/sbirt"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R96","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1093\/cid\/civ093","article-title":"Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review.","volume":"60","author":"Ford","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R97","unstructured":"Borges CM, Crawley A, Castro MA, Blan S, Braunstein S, Pathela P. HIV incidence among MSM given PEP starter packs in NYC sexual health clinics, 2014\u201316 [Poster]. Presented at the 25th CROI Conference on Retroviruses and Opportunistic Infections, Boston, MA: March 4\u20137, 2018."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R98","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1093\/ofid\/ofy210.1134","article-title":"Evaluation of the rates of HIV post-exposure prophylaxis completion after the implementation of an automated referral system in the emergency department.","volume":"5","author":"Schwarz","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R99","doi-asserted-by":"publisher","first-page":"S524","DOI":"10.1093\/ofid\/ofaa439.1178","article-title":"992. Rethinking the 28-day HIV nPEP dispensing practice: a pediatric ID clinic analysis.","volume":"7","author":"Zhang","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R100","doi-asserted-by":"publisher","first-page":"e20164243","DOI":"10.1542\/peds.2016-4243","article-title":"Care of the adolescent after an acute sexual assault.","volume":"139","author":"Crawford-Jakubiak","year":"2017","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R101","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1542\/peds.2013-1741","article-title":"The evaluation of children in the primary care setting when sexual abuse is suspected.","volume":"132","author":"Jenny","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R102","first-page":"275","article-title":"Nonoccupational post-exposure prophylaxis offer, acceptance, and adherence in sexual assault victims.","volume":"24","author":"Bucossi","year":"2017","journal-title":"Acad Emerg Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajem.2021.05.070","article-title":"Post-exposure prophylaxis for human immunodeficiency virus after sexual assault in a Midwestern U.S. emergency department.","volume":"49","author":"Cherabie","year":"2021","journal-title":"Am J Emerg Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R104","doi-asserted-by":"publisher","first-page":"S346","DOI":"10.1016\/j.biopsych.2018.02.890","article-title":"F276. Use of HIV post-exposure prophylaxis among women sexual assault survivors is not associated with increased posttraumatic stress symptoms.","volume":"83","author":"Singla","year":"2018","journal-title":"Biol Psychiatry"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R105","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1080\/09540121.2021.1957079","article-title":"nPEP protocol implementation and evaluation at a local US Crisis Center.","volume":"34","author":"Ortega","year":"2022","journal-title":"AIDS Care"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R106","unstructured":"Lowrey K, Kaucher K, Dawson J, Gilliam E. Improvement in HIV screening follow-up with emergency department pharmacist dispensing of post-exposure prophylaxis. Presented at the American College of Clinical Pharmacy (Virtual) annual meeting, October 19\u201330, 2020."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R107","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/hiv.13196","article-title":"Standardizing HIV post-exposure prophylaxis in the emergency department following sexual assault.","volume":"23","author":"Silva-Nash","year":"2022","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/JFN.0000000000000153","article-title":"A qualitative exploration of sexual assault patients\u2019 barriers to accessing and completing HIV prophylaxis.","volume":"13","author":"Djelaj","year":"2017","journal-title":"J Forensic Nurs"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R109","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.chiabu.2017.04.014","article-title":"Improving HIV post-exposure prophylaxis rates after pediatric acute sexual assault.","volume":"69","author":"Schilling","year":"2017","journal-title":"Child Abuse Negl"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R110","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jpids\/piaa033","article-title":"\u201cMeds-in-Hand\u201d intervention to reduce critical process delays in pediatric human immunodeficiency virus post-exposure prophylaxis.","volume":"10","author":"Epstein","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R111","doi-asserted-by":"publisher","first-page":"104143","DOI":"10.1016\/j.chiabu.2019.104143","article-title":"Adherence to HIV post-exposure prophylaxis for children\/adolescents who have been sexually assaulted: A systematic review of barriers, enablers, and interventions.","volume":"116","author":"Shubber","year":"2021","journal-title":"Child Abuse Negl"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R112","unstructured":"Rape, Abuse & Incest National Network. Find help near you. Washington, DC: Rape, Abuse & Incest National Network; 2021. https:\/\/rainn.org"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R113","unstructured":"CDC. About sexual violence. US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/sexual-violence\/about"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R114","unstructured":"US Department of Justice. A national protocol for sexual assault medical forensic examinations: adults\/adolescents. Washington, DC: US Department of Justice, Office on Violence Against Women; 2013. https:\/\/www.ojp.gov\/pdffiles1\/ovw\/228119.pdf"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R115","unstructured":"US Department of Justice. Victim compensation and assistance in your state. Washington, DC: US Department of Justice, Office for Victims of Crime. https:\/\/ovc.ojp.gov\/help-for-victims\/help-in-your-state"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R116","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2022.10777","article-title":"Minor consent laws for sexually transmitted infection and HIV services.","volume":"328","author":"Nelson","year":"2022","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R117","unstructured":"CDC. Persons who inject drugs (PWID). US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/persons-who-inject-drugs\/about\/index.html"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R118","unstructured":"Substance Abuse and Mental Health Services Administration. SAMHSA\u2019s National Helpline. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/find-help\/helplines\/national-helpline"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R119","unstructured":"CDC. HIV treatment and hormone therapy. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/hiv\/treatment\/index.html#cdc_treatment_animal-treatment-side-effects-and-interactions"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R120","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/00918369.2019.1696105","article-title":"Biomedical HIV prevention among gay male couples: a qualitative study of motivations and concerns.","volume":"68","author":"Bosco","year":"2021","journal-title":"J Homosex"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R121","unstructured":"Walsh A, Chavanduka T, Sallabank G, , editors. Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: the iREACH Study. J Int AIDS Soc 2021:24. Chichester, England: John Wiley & Sons."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R122","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/JHQ.0000000000000260","article-title":"Improving emergency access to human immunodeficiency virus prophylaxis for patients evaluated after sexual assault.","volume":"43","author":"Saadatzadeh","year":"2021","journal-title":"J Healthc Qual"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jen.2017.10.014","article-title":"The priority of administering HIV postexposure prophylaxis in cases of sexual assault in an emergency department.","volume":"44","author":"Scannell","year":"2018","journal-title":"J Emerg Nurs"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R124","doi-asserted-by":"publisher","first-page":"S522","DOI":"10.1093\/ofid\/ofaa439.1173","article-title":"987. Improving patient access to HIV post-exposure prophylaxis with pharmacist involvement.","volume":"7","author":"Grossman","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R125","unstructured":"Jakubowski IL, Soloway ML, Guzman CF,  HIV prevention and drug-user health care on site at a syringe exchange program. Presented at the 25th CROI Conference on Retroviruses and Opportunistic Infections, Boston, MA: March 8\u201311, 2020."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R126","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.japh.2019.06.021","article-title":"Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health.","volume":"60","author":"Lopez","year":"2020","journal-title":"J Am Pharm Assoc (Wash DC)"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R127","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QAI.0000000000001639","article-title":"Brief report: HIV postexposure prophylaxis-in-pocket (\u201cPIP\u201d) for individuals with low-frequency, high-risk HIV exposures.","volume":"78","author":"Tumarkin","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R128","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/QAD.0000000000002441","article-title":"HIV postexposure prophylaxis-in-pocket: long-term follow-up of individuals with low-frequency, high-risk HIV exposures.","volume":"34","author":"Alghamdi","year":"2020","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/QAI.0000000000003282","article-title":"Brief report: outcomes of individuals using HIV postexposure prophylaxis-in-pocket (\u201cPIP\u201d) for low-frequency, high-risk exposures in Toronto, Canada.","volume":"94","author":"Billick","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R130","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/09564624231215151","article-title":"Appropriate usage of post-exposure prophylaxis-in-pocket for HIV prevention by individuals with low-frequency exposures.","volume":"35","author":"Clifford Rashotte","year":"2024","journal-title":"Int J STD AIDS"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R131","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/sextrans-2022-055622","article-title":"Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy.","volume":"99","author":"Fox","year":"2023","journal-title":"Sex Transm Infect"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R132","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QAI.0000000000001440","article-title":"Optimal HIV postexposure prophylaxis regimen completion with single tablet daily elvitegravir\/cobicistat\/tenofovir disoproxil fumarate\/emtricitabine compared with more frequent dosing regimens.","volume":"75","author":"Mayer","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R133","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1071\/SH16132","article-title":"Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system.","volume":"14","author":"Pierce","year":"2017","journal-title":"Sex Health"},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R134","unstructured":"Vii V Healthcare. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use. [Package insert.] Durham, NC: ViiV Healthcare; 2021."},{"key":"key-10.15585\/mmwr.rr7401a1-202505201510-R135","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","article-title":"The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.","volume":"28","author":"Siegler","year":"2018","journal-title":"Ann Epidemiol"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:15:15Z","timestamp":1747754115000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/rr\/rr7401a1.htm?s_cid=rr7401a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":282,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr7401a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,8]]},"published":{"date-parts":[[2025,5,8]]}}}